Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

U.S. FDA grants Priority Review to sBLA for PADCEV + Keytruda as perioperative treatment for...

Trastuzumab Ruikang has received BTD from China’s NMPA for the treatment of HER2‑positive breast cancer

SHR‑A2102 has received BTD from China’s NMPA for the treatment of cervical cancer

Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment...

Servier completes the acquisition of Day One Biopharmaceuticals